Clinical Trials Logo

Hepatocellular Carcinoma (HCC) clinical trials

View clinical trials related to Hepatocellular Carcinoma (HCC).

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05889949 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma (HCC)

Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma

Start date: June 1, 2019
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to explore the role of prediction of microvascular invasion by radiomics based on pre-treatment magnetic resonance imaging for guiding treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.

NCT ID: NCT04639180 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma (HCC)

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Start date: April 1, 2021
Phase: Phase 3
Study type: Interventional

A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.

NCT ID: NCT04522908 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma (HCC)

Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function

Start date: October 12, 2020
Phase: Phase 2
Study type: Interventional

Open-label, single arm, multicenter phase II trial assessing the tolerability of a reduced starting dose of 40 mg cabozantinib for 4 weeks and subsequent dose escalation to 60 mg cabozantinib until disease progression or intolerable toxicities.

NCT ID: NCT03753659 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma (HCC)

IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

Start date: May 9, 2019
Phase: Phase 2
Study type: Interventional

This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity of peri-interventional treatment with the anti-PD1 antibody pembrolizumab in HCC patients who are candidates for local ablation via either radiofrequency ablation (RFA) or microwave ablation (MWA) or brachytherapy or combination of TACE with RFA, MWA or brachytherapy.